<DOC>
	<DOC>NCT01665144</DOC>
	<brief_summary>Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerabiilty and efficacy (Extension Part).</brief_summary>
	<brief_title>Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
	<criteria>Prior history of relapsing remitting MS SPMS defined as progressive increase of disability over at least 6 months EDSS score of 3.0 to 6.5 No relapse of corticosteroid treatment within 3 months Women of child bearing potential must use reliable forms of contraception. Diagnosis of Macular edema during screening period Any medically unstable condition determined by investigator. Unable to undergo MRI scans Hypersensitivity to any study drugs or drugs of similar class Other protocol defined inclusion/exclusion may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Secondary Progressive Multiple Sclerosis</keyword>
</DOC>